Clinical Trial: AMG 162 in Biphosphonate Naive Metastatic Breast Cancer


	Home	\|	Search	\|	Browse	\|	Resources	\|	Help	\|	What's New	\|	About

AMG 162 in Biphosphonate Naive Metastatic Breast Cancer

This study is currently recruiting patients.

Sponsored by:	Amgen
Information provided by:	Amgen

Purpose

This study is to evaluate various doses and schedules for AMG 162 administration and characterize the safety profile in this indication.

Condition	Treatment or Intervention	Phase
Breast Cancer Metastases	Drug: AMG 162	Phase II

Study Type: Interventional
Study Design: Treatment

Eligibility

Ages Eligible for Study: 18 Years and above, Genders Eligible for Study: Female

Criteria

Inclusion Criteria:

Confirmed breast cancer
At least one bone metastasis

Location and Contact Information

Amgen Call Center 866-572-6436

Florida
Research Site, Ormond Beach, Florida, United States; Recruiting

Oregon
Research Site, Portland, Oregon, United States; Recruiting

Virginia
Research Site, Abingdon, Virginia, United States; Recruiting

Washington
Research Site, Seattle, Washington, United States; Recruiting

More Information

AmgenTrials clinical trials website

Center Watch Clinical Trials Listing Service

Study ID Numbers: 20040113
Record last reviewed: September 2004
Record first received: September 17, 2004
ClinicalTrials.gov Identifier: NCT00091832
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2004-11-09

U.S. National Library of Medicine, Contact NLM Customer Service

National Institutes of Health, Department of Health & Human Services